Clinical trials: in Croatia
Bronchiectasis
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
- Trial name
- NCT06872892
- Testing
- BI 1291583
- Where
- 478 sites in United States, Argentina and 44 more
- Volunteers
- 1,755 people
- Sponsor
- Boehringer Ingelheim
Proteinuric Kidney Diseases
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and…
- Trial name
- NCT07355296
- Testing
- BI 764198
- Where
- 154 sites in United States, Argentina and 30 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Coherent Sine Burst (CSE) Electroporation System Pilot Study in Patients With Atrial Fibrillation
To evaluate the safety and efficiency of the Arga Medtech CSE Ablation System in the treatment of atrial fibrillation.
- Trial name
- BURST-AF (NCT05572047)
- Testing
- Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
- Where
- 3 sites in Croatia, Georgia
- Volunteers
- 101 people
- Sponsor
- Arga Medtech SA
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or…
- Trial name
- FIBRONEER™-ON (NCT06238622)
- Testing
- Nerandomilast
- Where
- 375 sites in United States, Argentina and 42 more
- Volunteers
- 1,666 people
- Sponsor
- Boehringer Ingelheim
Systemic Lupus Erythematosus
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE.
- Trial name
- NCT07409181
- Testing
- BI 3000202
- Where
- 139 sites in United States, Argentina and 19 more
- Volunteers
- 405 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety…
- Trial name
- OLERO (NCT05269004)
- Testing
- Ocrelizumab
- Where
- 232 sites in United States, Argentina and 35 more
- Volunteers
- 1,300 people
- Sponsor
- Hoffmann-La Roche
Glycogen Storage Disease Type II, Pompe Disease
Pompe Disease Registry Protocol
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both…
- Trial name
- NCT00231400
- Where
- 282 sites in United States, Argentina and 42 more
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- CAPTIVATE (NCT06858579)
- Testing
- Claseprubart
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 256 people
- Sponsor
- Dianthus Therapeutics
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 872 sites in United States, Australia and 45 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Alzheimer Disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
- Trial name
- NCT06585787
- Testing
- KarXT
- Where
- 296 sites in United States, Argentina and 23 more
- Volunteers
- 406 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis, Inflammatory Bowel Diseases
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Trial name
- SKYLINE-UC (NCT07012395)
- Testing
- SPY001, SPY002, SPY003
- Where
- 276 sites in United States, Argentina and 33 more
- Volunteers
- 645 people
- Sponsor
- Spyre Therapeutics, Inc.
Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation
OPTION-EMEA Clinical Trial
The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with…
- Conditions
- Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Pulsed Field Ablation
- Trial name
- OPTION-EMEA (NCT07349121)
- Testing
- Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case, Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure
- Where
- 11 sites in Belgium, Croatia and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Hemophilia A, Hemophilia B
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study…
- Trial name
- NCT05145127
- Testing
- PF-06741086
- Where
- 78 sites in United States, Argentina and 22 more
- Volunteers
- 245 people
- Sponsor
- Pfizer
Bipolar Disorder Type I With Mania
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the…
- Trial name
- NCT06929273
- Testing
- KarXT, Lithium, Valproate
- Where
- 184 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Bristol-Myers Squibb
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's…
- Trial name
- SIBERITE-2 (NCT06819891)
- Testing
- Afimkibart
- Where
- 208 sites in United States, Argentina and 25 more
- Volunteers
- 425 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
- Trial name
- NCT07211633
- Testing
- Ublituximab
- Where
- 48 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 360 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02970318
- Testing
- Acalabrutinib (ACP-196), Rituximab, Idelalisib
- Where
- 157 sites in United States, Australia and 23 more
- Volunteers
- 310 people
- Sponsor
- Acerta Pharma BV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.